Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...

Clear Channel Outdoor Holdings, Inc., (NYSE:CCO) announced today that Scott Wells, Chief Executive Officer of Clear Channel ...

Indian equity markets closed lower for the eighth consecutive session on Friday, weighed down by new tariff threats from the US. US President Donald Trump vowed to impose reciprocal tariffs on every ...

New Delhi: Glenmark Pharmaceuticals on Friday said its subsidiary has launched generic medication to treat glaucoma in the US ...

Glenmark Pharma introduces generic Xalatan ophthalmic solution, 0.005% in US: Our Bureau, Mumbai Friday, February 14, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Gle ...

Glenmark launches Latanoprost Ophthalmic Solution, targeting $113.5 million market, showcasing commitment to quality eye care ...

Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in ...

Glenmark Pharmaceuticals launches a generic ophthalmic solution for glaucoma in the US market, adding to its growing ...

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.